2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…2019 American Transplant Congress
Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation
Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Recent observations suggest that the use of IVIg + rituximab has a critical role in modifying allo-reactive B-cells prior to HLAi kidney transplantation, thus…2019 American Transplant Congress
Resolution of Hyperglycemia Following Islet Allograft Transplantation in Non-Immunosuppressed Mice
*Purpose: Kidney allografts are naturally tolerogenic in mice. Certain mouse strain combinations develop tolerance of kidney allografts across full MHC incompatibilities without immunosuppression (e.g. DBA/2…2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…2019 American Transplant Congress
B Cell IL-4 Signaling Induces the IL-10 Secreting TIM-1+ Bregs and Suppresses T Cell Inflammatory Cytokines
Surgery, Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: TIM-1+ identifies the majority (~75%) of IL-10+ B regulatory cells (Bregs). However, TIM-1+ B cells are also enriched for IL-4+ B effector 2 cells…2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…2019 American Transplant Congress
Alloreactive B Cells in Transplant Tolerant Recipients Cannot Differentiate into Antibody-Secreting Cells but Can Suppress Donor-Specific IgG Production By Naïve B Cells
*Purpose: Donor specific transplantation tolerance has long been the goal of clinical transplantation. Clinical observations suggest that donor-specific antibodies (DSA) are a major cause of…2019 American Transplant Congress
Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis
Severance hospital, Seoul, Korea, Republic of
*Purpose: Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. We sought to explore the effects of rituximab…2019 American Transplant Congress
RNA Sequencing Guided Identification of Shared mRNAs in Human Kidney Allograft Recipients with Acute T Cell Mediated Rejection or Active Antibody Mediated Rejection
*Purpose: T cell help is essential for B cell production of antibodies to donor organ HLA. Because T cell-B cell interactions contribute to anti-allograft immunity,…2019 American Transplant Congress
Cellular And Molecular Characteristics Of Intra-graft Lymphoid Aggregates In Chronic Lung Allograft Dysfunction
*Purpose: Lymphoid aggregates (LAs) have been identified within lung allografts post lung transplant (LTx). However, it remains controversial whether they represent benign lymphoid tissue or…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 35
- Next Page »